Publication Date:
2017-05-04
Description:
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Nature 545, 7652 (2017). doi:10.1038/nature22079 Authors: Alexander C. Huang, Michael A. Postow, Robert J. Orlowski, Rosemarie Mick, Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R. Giles, Brandon Wenz, Matthew Adamow, Deborah Kuk, Katherine S. Panageas, Cristina Carrera, Phillip Wong, Felix Quagliarello, Bradley Wubbenhorst, Kurt D’Andrea, Kristen E. Pauken, Ramin S. Herati, Ryan P. Staupe, Jason M. Schenkel, Suzanne McGettigan, Shawn Kothari, Sangeeth M. George, Robert H. Vonderheide, Ravi K. Amaravadi, Giorgos C. Karakousis, Lynn M. Schuchter, Xiaowei Xu, Katherine L. Nathanson, Jedd D. Wolchok, Tara C. Gangadhar & E. John Wherry Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used as indicators of clinical response; however, blood-based
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink